INTRAVESICAL OXYBUTYNIN FOR NEUROGENIC BLADDER DYSFUNCTION: LESS SYSTEMIC SIDE EFFECTS DUE TO REDUCED FIRST PASS METABOLISM-Reference-Cited by-同舟云学术

INTRAVESICAL OXYBUTYNIN FOR NEUROGENIC BLADDER DYSFUNCTION: LESS SYSTEMIC SIDE EFFECTS DUE TO REDUCED FIRST PASS METABOLISM

Published:1998-09 Issue:3 Part 1 Volume:160 Page:892-896
ISSN:0022-5347
Container-title:Journal of Urology
language:en
Short-container-title:Journal of Urology

Author:

BUYSE GUNNAR¹,WALDECK KRISTIAN¹,VERPOORTEN CARLA¹,BJORK HENRIK¹,CASAER PAUL¹,ANDERSSON KARL-ERIK¹

Affiliation:

1. From the Division of Paediatric Neurology, Department of Paediatrics, University Hospital Gasthuisberg, Leuven, Belgium, and the Department of Clinical Pharmacology, Lund University Hospital, Lund, Sweden

Publisher

Ovid Technologies (Wolters Kluwer Health)

Subject

Urology

Reference18 articles.

1. Management of the obstructed urinary tract associated with neurogenic bladder dysfunction;Bauer;Urol. Clin. N. Am.,1990

2. Neurogenic bladder dysfunction in children: review of pathophysiology and current management;Fernandes;J. Pediatr.,1994

3. Oxybutynin: a review of its pharmacodynamic and pharmacokinetic properties, and its therapeutic use in detrusor instability;Yarker;Drugs Aging,1995

4. Topical oxybutynin chloride for relaxation of dysfunctional bladders;Brendler;J. Urol.,1989

5. The use of intravesical oxybutynin chloride in children with neurogenic bladders;Greenfield;J. Urol.,1991

Cited by 122 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Harninkontinenz;AkupunkturPraxis;2023-08

2. Treating Lower Urinary Tract Symptoms in Older Adults: Intravesical Options;Drugs & Aging;2023-03

3. Kurzfassung der S2k-Leitlinie medikamentöse Therapie der neurogenen Dysfunktion des unteren Harntraktes (NLUTD);Die Urologie;2022-10-21

4. Dosing Variability and Clinical Outcomes of Oxybutynin: A Pediatric Cohort of Patients With Neurogenic Bladder;Topics in Spinal Cord Injury Rehabilitation;2022-06-01

5. Nanotechnology as a tool to advance research and treatment of non-oncologic urogenital diseases;Therapeutic Advances in Urology;2022-01